ALPINE IMMUNE SCIENCES, INC.: directors' dealings · United States · SEC (Form 4)

About ALPINE IMMUNE SCIENCES, INC.

Alpine Immune Sciences, Inc. (ALPN) was a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. Before its acquisition by Vertex in May 2024, Alpine focused on discovering and developing innovative, protein-based immunotherapies for autoimmune and inflammatory diseases. The company was headquartered in Seattle, Washington, which placed it in one of the country’s most important biotech hubs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1626199/000162619923000088/alpn-20230630.htm?utm_source=openai)) Alpine’s corporate history is tied to its combination with Nivalis Therapeutics, completed in July 2017, but its modern identity was built around internal protein-engineering capabilities and a platform-driven approach to immune modulation. In practical terms, Alpine operated as a niche precision-immunology biotech: small enough to remain highly focused, yet ambitious enough to compete in a crowded field where scientific differentiation and clinical execution determine value creation. Its strategic positioning was based on generating assets with strong mechanistic rationale and the potential to address serious chronic diseases with high unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm?utm_source=openai)) The company’s lead asset was povetacicept, which management and external materials described as having “pipeline-in-a-product” potential because it could potentially serve multiple autoimmune indications. The most visible development focus was IgA nephropathy, while other possible applications included additional immune-mediated disorders. Alpine also had acazicolcept (ALPN-101) in its portfolio under an option and license arrangement with AbbVie, which provided a potential partnering and monetization pathway beyond its lead program. This mix of internal development and strategic partnering is typical of U.S. biotech companies seeking to balance scientific ambition with capital efficiency. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm?utm_source=openai)) In competitive terms, Alpine operated in a highly contested immunology market, where large pharmaceutical groups and specialized biotechs compete on efficacy, safety, and breadth of indication. Alpine’s edge was its protein-engineering platform, the quality of its clinical data, and the possibility of using a single engineered molecule across several related diseases. Throughout 2023 and early 2024, the company emphasized progress toward more advanced development stages for povetacicept, which increased strategic interest in the asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1626199/000162619924000048/alpn-20231231.htm?utm_source=openai)) The most important recent event was Vertex’s definitive agreement announced on April 10, 2024, to acquire Alpine for approximately $4.9 billion in cash, or $65 per share, followed by closing on May 20, 2024. As a result, Alpine ceased to operate as an independent public company after that date, although its SEC filing history, clinical legacy, and insider-transaction record remain relevant for investors analyzing biotech M&A and U.S. listed healthcare names. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1626199/0001193125-24-091936-index.htm?utm_source=openai))